Abstract
Prostate cancer is the leading non-cutaneous malignancy in American men. Only the combination of docetaxel and prednisone has been shown to improve survival in patients with metastatic castration-resistant prostate cancer. Typically responses to docetaxel in patients with castrate-resistant disease are modest and additional therapies are needed. Angiogenesis has been shown to be a prerequisite event for tumor growth and metastasis in prostate cancer. Several strategies have been used to target angiogenesis in prostate cancer, which include blocking of pro-angiogenic factors via monoclonal antibodies or small-molecule inhibitors that target downstream signaling pathways for angiogenesis, direct inhibition of endothelial cells, or targeting other receptors involved in cell adhesion, proliferation, and survival. The following sections will discuss further the rationale for targeting the angiogenesis pathway in prostate cancer and the emergence of bevacizumab as a promising agent for the treatment of prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
